EGFR and non-small cell lung carcinoma: On these bases, IFCT-1503 ACE-Lung, a randomised and open-label phase 2 study, has been designed to compare afatinib plus cetuximab versus the afatinib single agent as a first-line therapy of advanced EGFR-mutant NSCLC.